Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616000846426
Ethics application status
Approved
Date submitted
20/06/2016
Date registered
29/06/2016
Date last updated
29/11/2018
Date data sharing statement initially provided
29/11/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Dose escalation, placebo-controlled phase 1 study to assess the safety and tolerability of CSL324 in healthy adults
Scientific title
A single dose ascending and repeated dose, randomised, double-blind, placebo-controlled study to assess the safety, pharmacokinetics and pharmacodynamics of CSL324 in healthy, adult male and female subjects.
Secondary ID [1] 289161 0
CSL324_1001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Inflammatory and immune system disorders 298692 0
Condition category
Condition code
Inflammatory and Immune System 298747 298747 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The study will consist of 3 parts (Parts A, B and C). Subjects can participate in only 1 part and in only 1 dose group; in each part, subjects will be randomly assigned to either CSL324 or placebo. In Parts A and B a single infusion of either CSL324 or placebo will be administered; dose escalation may occur in these parts. There may be up to 6 subjects per dose in Parts A and B. In Part C, 10 subjects will receive 3 infusions at 21 day intervals of either CSL324 or placebo (according to their randomisation and at the same dose per infusion).

Intervention 1: Single (Parts A and B) or repeat (Part C) dose(s) of anti-human granulocyte-colony stimulating factor (G-CSF) receptor monoclonal antibody (CSL324) will be administered intravenously. The dose and infusion volume will be based upon the subject's body weight and the allowable drug concentration. Dose escalation requires Safety Review Committee review (of available blinded safety, tolerability, PK and selected PD data) and approval.

In addition to CSL324 or placebo, subjects may also receive other interventions (G-CSF and/or Cantharidin) as described below.

Intervention 2: Filgrastim (Registered Trademark: Neupogen), a recombinant form of human G-CSF, will be administered subcutaneously once a day, at approximately the same time each day on up to 6 consecutive days (from 3 days before and/or up to 3 days after CSL324 or placebo infusion depending upon the CSL324 or placebo dose amount) at a dose based upon the subject's body weight (5 microgram/kg; all Part B subjects only)

Intervention 3: Cantharidin (Registered Trademark: Cantharone), will be applied topically to the skin (on the arm), to induce a blister (all Parts A and B subjects only). Cantharidin (25 microlitres at 0.1 % weight/volume) will be administered once a day, on 2 separate days, 2 or 3 days apart (from 1 day before and up to 2 days after CSL324 or placebo infusion depending upon the CSL324 or placebo dose amount).
Intervention code [1] 294687 0
Treatment: Drugs
Comparator / control treatment
Placebo (saline) will be administered as an IV infusion at the same frequency, volume and duration as the CSL324 infusion(s) in Parts A, B and C.
Control group
Placebo

Outcomes
Primary outcome [1] 298229 0
Percentage of subjects with adverse events (AEs) overall and by relatedness and severity.
AEs will be assessed through evaluation of physical and neurological examinations, vital signs, electrocardiograms, clinical laboratory parameters, and monitoring of AEs. AEs will be recorded during the study and summarised by relatedness and severity using descriptive statistics.
Timepoint [1] 298229 0
For the duration of the subject's participation in the study, up to 5 months per subject
Secondary outcome [1] 323596 0
Area under the plasma concentration versus time curve (AUC) of CSL324 from the time of dosing extrapolated to time infinity (AUC0-inf) (Parts A and B)
Timepoint [1] 323596 0
Before study drug infusion, at the end of infusion, and at approximately 6, 12, 24, 36, 48, 72 and 96 hours after the end of infusion, and at approximately 8, 11, 15, 23, 29, 41, 51 and 85 days after infusion
Secondary outcome [2] 323597 0
Area under the plasma concentration versus time curve of CSL324 from the time of dosing up to collection time t (AUC0-t)
Timepoint [2] 323597 0
Parts A and B: Before study drug infusion, at the end of infusion, and at approximately 6, 12, 24, 36, 48, 72 and 96 hours after the end of infusion, and at approximately 8, 11, 15, 23, 29, 41, 51 and 85 days after infusion
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.
Secondary outcome [3] 323603 0
Area under the plasma concentration versus time curve of CSL324 during dosing interval at steady state (AUC0-tau; Part C).
AUC0-tau will be derived from serum CSL324 concentration-time profiles.
Timepoint [3] 323603 0
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.
Secondary outcome [4] 323604 0
Maximum serum CSL324 concentration (Cmax; Parts A and B), and Cmax at steady state (Cmax,ss; Part C)
Timepoint [4] 323604 0
Parts A and B: Before study drug infusion, at the end of infusion, and at approximately 6, 12, 24, 36, 48, 72 and 96 hours after the end of infusion, and at approximately 8, 11, 15, 23, 29, 41, 51 and 85 days after infusion.
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.
Secondary outcome [5] 323605 0
Clearance of CSL324 (CLtot; Parts A and B), and Clearance at steady state (Cltot,ss; Part C).
Clearance will be derived from the serum CSL324 concentration-time profiles.
Timepoint [5] 323605 0
Parts A and B: Before study drug infusion, at the end of infusion, and at approximately 6, 12, 24, 36, 48, 72 and 96 hours after the end of infusion, and at approximately 8, 11, 15, 23, 29, 41, 51 and 85 days after infusion.
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.
Secondary outcome [6] 323606 0
Time to maximum serum CSL324 concentration (Tmax; Parts A and B), and Tmax at steady state (Tmax,ss; Part C)
Timepoint [6] 323606 0
Parts A and B: Before study drug infusion, at the end of infusion, and at approximately 6, 12, 24, 36, 48, 72 and 96 hours after the end of infusion, and at approximately 8, 11, 15, 23, 29, 41, 51 and 85 days after infusion.
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.
Secondary outcome [7] 323607 0
Terminal elimination half-life of CSL324 (t1/2; Parts A and B), and t1/2 at steady state (T1/2,ss; Part C).
t1/2 will be derived from serum CSL324 concentration-time profiles.
Timepoint [7] 323607 0
Parts A and B: Before study drug infusion, at the end of infusion, and at approximately 6, 12, 24, 36, 48, 72 and 96 hours after the end of infusion, and at approximately 8, 11, 15, 23, 29, 41, 51 and 85 days after infusion.
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.
Secondary outcome [8] 323608 0
Volume of distribution (Vz; Parts A and B), and Vz at steady state during the terminal phase (Vz,ss; Part C).
Vz will be derived from serum CSL324 concentration-time profiles.
Timepoint [8] 323608 0
Parts A and B: Before study drug infusion, at the end of infusion, and at approximately 6, 12, 24, 36, 48, 72 and 96 hours after the end of infusion, and at approximately 8, 11, 15, 23, 29, 41, 51 and 85 days after infusion.
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.
Secondary outcome [9] 323609 0
Concentrations of CSL324 and G-CSF in cerebrospinal fluid (Part A only)
Timepoint [9] 323609 0
At approximately 3 days after the end of infusion of the last dose of study drug
Secondary outcome [10] 323610 0
Number of subjects with anti-CSL324 antibodies in serum
Timepoint [10] 323610 0
Parts A and B: Before study drug infusion and at approximately 29, 51 and 85 days after infusion.
Part C: Before each study drug infusion and at approximately 20, 27 and 83 days after the last infusion.
Secondary outcome [11] 323611 0
Maximum neutrophil concentration after filgrastim dosing (Emax,ANC; Part B).
Maximum effect of blood absolute neutrophil count after filgrastim dosing will be assessed using non-compartmental method
Timepoint [11] 323611 0
Before each filgrastim infusion, and at approximately 8 hours after filgrastim infusions 1 to 5, and at approximately 8, 12 and 24 hours after the last filgrastim infusion.
Secondary outcome [12] 323612 0
Area under the effect curve for absolute neutrophil count after filgrastim dosing (AUEC0-24,ANC; Part B).
AUEC0-24, ANC for blood absolute neutrophil count after filgrastim dosing will be assessed using non-compartmental method.
Timepoint [12] 323612 0
Before each filgrastim infusion, and at approximately 8 hours after filgrastim infusions 1 to 5, and at approximately 8, 12 and 24 hours after the last filgrastim infusion.
Secondary outcome [13] 325111 0
Minimum (trough) serum CSL324 concentration at steady state (Cmin,ss; Part C)
Timepoint [13] 325111 0
Part C: Before each study drug infusion, at the end of infusion for the 1st and 3rd infusions, at 1, 2, 4 and approximately 7 days after the 1st infusion, at 1 and approximately 7 days after the 2nd infusion, and at approximately 6 hours and at approximately 1, 2, 6, 13, 20, 27 and 83 days after the 3rd infusion.

Eligibility
Key inclusion criteria
- Healthy, male or female, 18 to 55 years of age
- Body mass index range of 18.5 to 32.0 kg/m^2, inclusive, and weight at least 50 kg and less than 100 kg
- Females must be of non-childbearing potential
- Male subject and their female spouse/partners who are of childbearing potential must be using 2 forms of highly effective birth control
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- History or evidence of any clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease or malignancy
- History of venous thrombosis, polycythaemia or thrombophilia
- History of autoimmune disease with the exception of seasonal allergic rhinitis managed without systemic glucocorticoid treatment
- Any history of cyclic neutropenia or a Screening absolute neutrophil count < 2.0 × 10^9/L

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Other
Other design features
Sequential single ascending dose groups (Parts A and B); repeat dose group (Part C).
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
30/06/2016
Actual
30/06/2016
Date of last participant enrolment
Anticipated
Actual
17/08/2017
Date of last data collection
Anticipated
4/01/2018
Actual
2/01/2018
Sample size
Target
58
Accrual to date
Final
56
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 293551 0
Commercial sector/Industry
Name [1] 293551 0
CSL Limited
Country [1] 293551 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
CSL Limited
Address
45 Poplar Rd,
Parkville, VIC 3052
Country
Australia
Secondary sponsor category [1] 292365 0
None
Name [1] 292365 0
Address [1] 292365 0
Country [1] 292365 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 294990 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 294990 0
Ethics committee country [1] 294990 0
Australia
Date submitted for ethics approval [1] 294990 0
Approval date [1] 294990 0
12/05/2016
Ethics approval number [1] 294990 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 65694 0
Dr Jason Lickliter
Address 65694 0
Nucleus Network
89 Commercial Road
Melbourne, VIC 3004
Country 65694 0
Australia
Phone 65694 0
+61 3 9076 8960
Fax 65694 0
Email 65694 0
[email protected]
Contact person for public queries
Name 65695 0
Biljana Georgievska
Address 65695 0
Nucleus Network
89 Commercial Road,
Melbourne VIC 3004
Country 65695 0
Australia
Phone 65695 0
1800 243 733
Fax 65695 0
Email 65695 0
[email protected]
Contact person for scientific queries
Name 65696 0
Biljana Georgievska
Address 65696 0
Nucleus Network
89 Commercial Road,
Melbourne VIC 3004
Country 65696 0
Australia
Phone 65696 0
1800 243 733
Fax 65696 0
Email 65696 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Individual Participant Data (IPD) will not be shared.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseCSL324, a granulocyte colony-stimulating factor receptor antagonist, blocks neutrophil migration markers that are upregulated in hidradenitis suppurativa.2023https://dx.doi.org/10.1093/bjd/ljad013
N.B. These documents automatically identified may not have been verified by the study sponsor.